SYN Synthetic Biologics, Inc. Commo

0.72
+0  (2%)
Previous Close 0.70
Open 0.72
Price To book 21.26
Market Cap 84.32M
Shares 117,541,000
Volume 192,335
Short Ratio 17.54
Av. Daily Volume 698,868

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 2 trial commenced October 2015. 12 week data met endpoints. Phase 2b/3 trial planned for 2017.
SYN-010
Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Pending. Partner Meda has received the go-ahead from the FDA to conduct a Phase 2 proof of concept trial
Flupirtine
Fibromyalgia
License terminated following lack of efficacy shown February 2016
Trimesta
Relapsing-remitting MS in women
Phase 2b topline data released January 5, 2017. Primary endpoint met. Phase 3 trial to be initiated 1H 2018.
SYN-004
C. difficile Infection

Latest News

  1. SYNTHETIC BIOLOGICS, INC. Financials
  2. Synthetic Biologics to Present at the 29th Annual ROTH Conference
  3. Synthetic Biologics reports 4Q loss
  4. Synthetic Biologics reports 4Q loss
  5. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  6. Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results
  7. Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017
  8. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  9. Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference
  10. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Prin
  11. Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
  12. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  13. Synthetic Biologics C. Difficile Drug Trial Succeeds
  14. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
  15. Synthetic Biologics' C. difficile mid-stage study meets main goal
  16. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  17. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
  18. Synthetic Biologics to Present at the Biotech Showcase™ 2017 Conference
  19. Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
  20. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Prin